Daré Bioscience, Inc.
DARE
$2.89
-$0.095-3.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 86.56% | 91.22% | 81.89% | 5.61% | 2.54% |
| Total Depreciation and Amortization | 10.16% | 17.69% | 39.14% | 39.79% | 59.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 112.12% | -12.87% | -4.16% | 3.51% | -20.71% |
| Change in Net Operating Assets | 155.76% | -496.07% | -130.85% | -149.06% | -197.45% |
| Cash from Operations | 113.88% | 78.10% | 49.70% | -35.17% | -114.81% |
| Capital Expenditure | 8.96% | -2,389.92% | -1,497.75% | -988.38% | -897.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 8.96% | -2,389.92% | -1,497.75% | -988.38% | -897.46% |
| Total Debt Issued | -6.57% | -6.57% | -- | -- | -- |
| Total Debt Repaid | -73.41% | -343.41% | -- | -- | -- |
| Issuance of Common Stock | -95.74% | -87.99% | 429.16% | 261.81% | 692.47% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.05% | -- | -- | -- | -- |
| Cash from Financing | -97.23% | -43.11% | 698.08% | 443.05% | 1,064.00% |
| Foreign Exchange rate Adjustments | -607.29% | -48.83% | 118.18% | 87.19% | 95.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 121.74% | 89.69% | 116.57% | 18.59% | -40.31% |